Muistin tukijärjestelmän toteutettavuustutkimus
Muistin tukijärjestelmän käyttöönotto: Toteutettavuustutkimus
The purpose of this study is to determining the feasibility of providing the Memory Support System (MSS) to individuals with mild cognitive impairment (MCI) and their partners at a clinic in Ontario, Canada. This will involve a) collecting information from patients referred to the a memory clinic and geriatric day hospital about the patient's interest in and the patient's preferred method to administer the MSS; and b) a cost analysis related to implementation of the MSS. The study will also measure efficacy outcomes of the MSS regarding program adherence as well as to self-reported IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden among a sample of individuals with MCI and their care partners
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
A survey will be created and sent out to participants with MCI who have expressed interest in participating in research and have been seen at a memory clinic or geriatric day hospital after the initiation of the study. The survey will consist of a Likert scale and open questions related to patient interest in and preferred length of MSS administration and preference for in-person versus virtual administration.
During and after collection of the survey data, a sample of 20 individuals with MCI (ages ≥50) and their care partners will undergo MSS training.
At enrollment in the MSS training, participants with MCI and their care partners will complete measures of cognitive and functional status. Participants and partners will also complete measures of treatment adherence, IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden at baseline, treatment end, and 8-week follow-up. Participants will complete the MSS training consisting of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after initial assessment. Training will be offered in English or French. After the intervention, participants and their partners will complete a semi-structured interview, seeking suggestions for improving the MSS, teaching curriculum, and intervention logistics.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Neil Thomas, MD
- Puhelinnumero: 613-562-6322
- Sähköposti: nthomas@bruyere.org
Tutki yhteystietojen varmuuskopiointi
- Nimi: Nayna Kirubakar
- Puhelinnumero: 1266 613-562-6262
- Sähköposti: nkirubakar@bruyere.org
Opiskelupaikat
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 5C8
- Rekrytointi
- Bruyère Health Research Institute
-
Ottaa yhteyttä:
- Neil Thomas, MD
- Puhelinnumero: 613-562-6322
- Sähköposti: nthomas@bruyere.org
-
Ottaa yhteyttä:
- Nayna Kirubakar
- Puhelinnumero: 1266 613-562-6262
- Sähköposti: nkirubakar@bruyere.org
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- diagnosis of single or multi-domain MCI
- Clinical Dementia Rating global (CDR) score of ≤ 0.5
- Montreal Cognitive Assessment score of ≥18
- available contact with a care partner ≥ 2 times weekly
- absence or stable intake of nootropic(s) for ≥ 3 months
Exclusion Criteria:
- visual/hearing impairment and/or history of reading or written inability/disability sufficient to interfere with MSS training
- concurrent participation in another related clinical trial
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Tukevaa hoitoa
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Muistin tukijärjestelmän osallistujat
|
The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Interest in completion of MSS training
Aikaikkuna: From study start date up to 19 months.
|
Percentage of participants that complete the feasibility survey and agree or strongly agree with the statement that they are interested in completing MSS training. |
From study start date up to 19 months.
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Adherence to French Memory Support System Intervention
Aikaikkuna: One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from adherence scores from one week after starting treatment (MSS intervention) at treatment end and at 8 weeks after the treatment end. Using an adherence scale from 0 to 10, with 10 being highest and a cut-off score of ≥ 7 points suggesting adherence with the MSS. |
One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Center for Epidemiologic Studies Depression Scale
Aikaikkuna: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Depression screening scale using Likert scale. Total score of 0-60 points, with higher scores signifying a worse outcome (higher levels of depression). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Everyday Cognition questionnaire.
Aikaikkuna: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report measure of performance based instrumental activities of daily living. Total score of 23-92, with higher scores indicating a worse outcome. |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Functional Assessment Questionnaire
Aikaikkuna: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based report of performance of instrumental activities of daily living. Total score of 0-30, with higher scores indicating a worse outcome (higher level of dependence). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Quality of Life in Alzheimer Disease
Aikaikkuna: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report quality of life scale. Total score of 13-52, with higher scores indicating a better outcome (better quality of life). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
State-Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project
Aikaikkuna: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report anxiety scale. Total score of 10-40 with higher scores indicating a worse outcome (higher level of anxiety). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Chronic Disease Self-efficacy Scale
Aikaikkuna: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Selected questions related to memory and cognition from self report scale. Total score of 9-90 with higher scores indicating a better outcomes (higher feeling of self-efficacy). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Caregiver Burden Inventory Short-Form
Aikaikkuna: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based scale of level of caregiver burden. Total score of 0-48 with higher scores indicating a worse outcome (higher level of burden). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Tutkijat
Tutkijat
- Päätutkija: Neil Thomas, MD, Bruyère Health Research Institute.
- Päätutkija: Octavio Santos, PhD, Ottawa Hospital Research Institute, Bruyère Health Research Institute
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- M16-23-024
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
De-identified data from the study may be shared with other researchers within the HABIT consortium. Data that may be shared will include the results of the feasibility survey and the scores from the baseline, treatment end and 8 week follow up outcome measures collected from participants who complete MSS training.
IPD-jaon aikakehys
Data will be available after the end date of the study and kept indefinitely.
IPD-jaon käyttöoikeuskriteerit
Upon request that is approved by the study principal investigators.
IPD-jakamista tukeva tietotyyppi
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .